Document:

<PAGE>
                                                                     EXHIBIT 4.4

THIS WARRANT AND THE SECURITIES REPRESENTED HEREBY OR ACQUIRABLE UPON EXERCISE
HEREOF HAVE NOT REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY
NOT BE OFFERED, SOLD, ASSIGNED OR TRANSFERRED, IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT UNDER SAID ACT OR UNLESS THE COMPANY HAS RECEIVED AN
OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT REGISTRATION
UNDER SAID ACT IS NOT REQUIRED.

                         SPECTRUM PHARMACEUTICALS, INC.

                                     WARRANT

DATED: APRIL 21, 2004                                            NUMBER: SPPI260

            Spectrum Pharmaceuticals, Inc., a Delaware corporation (the
"Company"), hereby certifies that, for value received, ANNA KAZANCHYAN or her
registered assigns ("Holder"), is entitled, subject to the terms set forth
below, to purchase from the Company up to a total of 25,000 shares of Common
Stock, $.001 par value per share (the "Common Stock"), of the Company (each such
share, a "Warrant Share" and all such shares, the "Warrant Shares") at an
exercise price equal to $11.50 per share (as adjusted from time to time as
provided in Section 9, the "Exercise Price"), at any time from and including
April 21, 2005 (the "Effective Date") through and including April 20, 2009 (the
"Expiration Date"), and subject to the following terms and conditions:

            1. Registration of Warrant. The Company shall register this Warrant
upon records to be maintained by the Company for that purpose (the "Warrant
Register"), in the name of the record Holder hereof from time to time. The
Company may deem and treat the registered Holder of this Warrant as the absolute
owner hereof for the purpose of any exercise hereof or any distribution to the
Holder, and for all other purposes, and the Company shall not be affected by
notice to the contrary.

            2. Registration of Transfers and Exchanges.

               (a) This Warrant may not be sold, transferred, assigned, pledged,
hypothecated or otherwise disposed, directly or indirectly, in whole or in part,
without the prior written consent of the Company. Any attempted sale, transfer,
assignment, pledge, hypothecation or other disposition of this Warrant, or any
portion thereof, shall be void and without any force or effect; provided,
however, that, subject to compliance with any applicable securities laws, the
Holder may transfer this Warrant, or any portion thereof, without the prior
written consent of the Company, if such transfer is to (i) a spouse, child,
grandchild, parent, sibling or custodian or trustee for the benefit of any such
relatives, or (ii) any shareholder or affiliate entity.

               (b) The Company shall register the transfer of any portion of
this Warrant in conformance with Section 2(a) in the Warrant Register, upon
surrender of this Warrant, with the Form of Assignment attached hereto duly
completed and signed, to the Company at the office specified in or pursuant to
Section 10. Upon any such registration or

                                       1
<PAGE>

transfer, a new warrant to purchase Common Stock, in substantially the form of
this Warrant (any such new warrant, a "New Warrant"), evidencing the portion of
this Warrant so transferred shall be issued to the transferee and a New Warrant
evidencing the remaining portion of this Warrant not so transferred, if any,
shall be issued to the transferring Holder. The acceptance of the New Warrant by
the transferee thereof shall be deemed the acceptance of such transferee of all
of the rights and obligations of a holder of this Warrant.

               (c) This Warrant is exchangeable, upon the surrender hereof by
the Holder to the office of the Company specified in or pursuant to Section 10
for one or more New Warrants, evidencing in the aggregate the right to purchase
the number of Warrant Shares which may then be purchased hereunder.

               (d) Each certificate for Warrant Shares initially issued upon the
exercise of this Warrant, and each certificate for Warrant Shares issued to any
subsequent transferee of any such certificate, unless, in each case, such
Warrant Shares are eligible for resale without registration pursuant to Rule
144(k) under the Exchange Act, or has been sold pursuant to and in compliance
with Rule 144 or an effective registration statement under the Securities Act,
shall bear the following legend:

               "THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
               REGISTERED UNDER THE SECURITIES ACT OF 1933 AS AMENDED, AND MAY
               NOT BE OFFERED, SOLD, ASSIGNED OR TRANSFERRED, IN THE ABSENCE OF
               AN EFFECTIVE REGISTRATION STATEMENT UNDER SAID ACT OR UNLESS THE
               COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY
               SATISFACTORY TO THE COMPANY THAT REGISTRATION UNDER SAID ACT IS
               NOT REQUIRED."

            3. Duration and Exercise of Warrant.

               (a) This Warrant shall be exercisable by the then registered
Holder on any business day before 5:00 P.M., California time, at any time and
from time to time on or after the Effective Date to and including the Expiration
Date. At 5:00 P.M., California time on the Expiration Date, the portion of this
Warrant not exercised prior thereto shall be and become void and of no value.

               (b) Upon surrender of this Warrant, with the Form of Election to
Purchase attached hereto duly completed and signed, to the Company at its
address for notice set forth in Section 10 and upon payment of the Exercise
Price multiplied by the number of Warrant Shares that the Holder intends to
purchase hereunder, in the manner provided hereunder, all as specified by the
Holder in the Form of Election to Purchase, the Company shall promptly (and in
any event, within four business days) issue or cause to be issued and cause to
be delivered to or upon the written order of the Holder and in such name or
names as the Holder may designate, a certificate for the Warrant Shares issuable
upon such exercise. Any person so designated by the Holder to receive Warrant
Shares shall be deemed to have become holder of record of such Warrant Shares as
of the Date of Exercise of this Warrant.

                                       2
<PAGE>

               A. "Date of Exercise" means the date on which the Company shall
have received (i) this Warrant (or any New Warrant, as applicable), with the
Form of Election to Purchase attached hereto (or attached to such New Warrant)
appropriately completed and duly signed, and (ii) payment of the Exercise Price
for the number of Warrant Shares so indicated by the holder hereof to be
purchased.

               (c) This Warrant shall be exercisable, either in its entirety or,
from time to time, for a portion of the number of Warrant Shares. If less than
all of the Warrant Shares which may be purchased under this Warrant are
exercised at any time, the Company shall issue or cause to be issued, at its
expense, a New Warrant evidencing the right to purchase the remaining number of
Warrant Shares for which no exercise has been evidenced by this Warrant.

               (d) Prior to the exercise of this Warrant, the Holder shall not
be entitled to any rights as a stockholder of the Company with respect to the
Warrant Shares, including (without limitation) the right to vote such shares,
receive dividends or other distributions thereon or be notified of stockholder
meetings (except as otherwise set forth in Section 7(f) herein).

               (e) If by the tenth business day after a Date of Exercise the
Company fails to deliver the required number of Warrant Shares in the manner
required pursuant to Section 3(b), then the Holder will have the right to
rescind such exercise.

            4. Payment of Taxes. The Company will pay any documentary stamp
taxes attributable to the issuance of Warrant Shares upon the exercise of this
Warrant; provided, however, that the Company shall not be required to pay any
tax which may be payable in respect of any transfer involved in the registration
of any certificates for Warrant Shares or Warrants in a name other than that of
the Holder. The Holder shall be responsible for all other tax liability that may
arise as a result of holding or transferring this Warrant or receiving Warrant
Shares upon exercise hereof.

            5. Replacement of Warrant. If this Warrant is mutilated, lost,
stolen or destroyed, the Company shall issue or cause to be issued in exchange
and substitution for and upon cancellation hereof, or in lieu of and
substitution for this Warrant, a New Warrant, but only upon receipt of evidence
reasonably satisfactory to the Company of such loss, theft or destruction and
indemnity, if requested, satisfactory to it. Applicants for a New Warrant under
such circumstances shall also comply with such other reasonable regulations and
procedures and pay such other reasonable charges as the Company may prescribe.

            6. Reservation of Warrant Shares. The Company covenants that it will
at all times reserve and keep available out of the aggregate of its authorized
but unissued Common Stock, solely for the purpose of enabling it to issue
Warrant Shares upon exercise of this Warrant as herein provided, the number of
Warrant Shares which are then issuable and deliverable upon the exercise of this
entire Warrant, free from preemptive rights or any other actual contingent
purchase rights of persons other than the Holder. The Company covenants that all
Warrant Shares that shall be so issuable and deliverable shall, upon issuance
and the payment of the

                                       3
<PAGE>

applicable Exercise Price in accordance with the terms hereof, be duly
authorized, validly issued and fully paid and nonassessable.

            7. Certain Adjustments. The Exercise Price and number of Warrant
Shares issuable upon exercise of this Warrant are subject to adjustment from
time to time as set forth in this Section 7. Upon each such adjustment of the
Exercise Price pursuant to this Section 7, the Holder shall thereafter prior to
the Expiration Date be entitled to purchase, at the Exercise Price resulting
from such adjustment, the number of Warrant Shares obtained by multiplying the
Exercise Price in effect immediately prior to such adjustment by the number of
Warrant Shares issuable upon exercise of this Warrant immediately prior to such
adjustment and dividing the product thereof by the Exercise Price resulting from
such adjustment.

               (a) If the Company, at any time while this Warrant is
outstanding, (i) shall pay a stock dividend (except scheduled dividends paid on
outstanding preferred stock which contain a stated dividend rate) or otherwise
make a distribution or distributions on shares of its Common Stock payable in
shares of Common Stock, (ii) subdivide outstanding shares of Common Stock into a
larger number of shares, or (iii) combine outstanding shares of Common Stock
into a smaller number of shares, the Exercise Price shall be multiplied by a
fraction of which the numerator shall be the number of shares of Common Stock
(excluding treasury shares, if any) outstanding before such event and the
denominator shall be the number of shares of Common Stock (excluding treasury
shares, if any) outstanding after such event. Any adjustment made pursuant to
this Section shall become effective immediately after the record date for the
determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a
subdivision or combination, and shall apply to successive subdivisions and
combinations.

               (b) In case of any reclassification of the Common Stock, any
consolidation or merger of the Company with or into another person, the sale or
transfer of all or substantially all of the assets of the Company or any
compulsory share exchange pursuant to which the Common Stock is converted into
other securities, cash or property, then the Holder shall have the right
thereafter to exercise this Warrant only into the shares of stock and other
securities and property receivable upon or deemed to be held by holders of
Common Stock following such reclassification, consolidation, merger, sale,
transfer or share exchange, and the Holder shall be entitled upon such event to
receive such amount of securities or property equal to the amount of Warrant
Shares such Holder would have been entitled to had such Holder exercised this
Warrant immediately prior to such reclassification, consolidation, merger, sale,
transfer or share exchange. The terms of any such consolidation, merger, sale,
transfer or share exchange shall include such terms so as to continue to give to
the Holder the right to receive the securities or property set forth in this
Section 7(b) upon any exercise following any such reclassification,
consolidation, merger, sale, transfer or share exchange.

               (c) If the Company, at any time while this Warrant is
outstanding, shall distribute to all holders of Common Stock (and not to holders
of this Warrant) evidences of its indebtedness or assets or rights or warrants
to subscribe for or purchase any security (excluding those referred to in
Sections 7(a), and (b)), other than as part of its dissolution or liquidation or
the winding up of its affairs, then in each such case the Exercise Price shall
be determined by

                                       4
<PAGE>

multiplying the Exercise Price in effect immediately prior to the record date
fixed for determination of stockholders entitled to receive such distribution by
a fraction of which the denominator shall be the fair market value of a share of
Common Stock determined as of the record date mentioned above, and of which the
numerator shall be the fair market value of a share of Common Stock determined
as of such record date less the fair market value at such record date of the
portion of such assets or evidence of indebtedness so distributed applicable to
one outstanding share of Common Stock as determined by the Company's independent
certified public accountants that regularly examines the financial statements of
the Company.

               (d) For the purposes of this Section 7, the following clauses
shall also be applicable:

                   (i)   Record Date. In case the Company shall take a record of
                         the holders of its Common Stock for the purpose of
                         entitling them (A) to receive a dividend or other
                         distribution payable in Common Stock or in securities
                         convertible or exchangeable into shares of Common
                         Stock, or (B) to subscribe for or purchase Common Stock
                         or securities convertible or exchangeable into shares
                         of Common Stock, then such record date shall be deemed
                         to be the date of the issue or sale of the shares of
                         Common Stock deemed to have been issued or sold upon
                         the declaration of such dividend or the making of such
                         other distribution or the date of the granting of such
                         right of subscription or purchase, as the case may be.

                   (ii)  Treasury Shares. The number of shares of Common Stock
                         outstanding at any given time shall not include shares
                         owned or held by or for the account of the Company, and
                         the disposition of any such shares shall be considered
                         an issue or sale of Common Stock.

               (e) All calculations under this Section 7 shall be made to the
nearest cent or the nearest 1/100th of a share, as the case may be.

               (f) If:

                   (i)   the Company shall declare a dividend (or any other
                         distribution) on its Common Stock; or

                   (ii)  the Company shall declare a special nonrecurring cash
                         dividend on or a redemption of its Common Stock; or

                   (iii) the Company shall authorize the granting to all holders
                         of the Common Stock rights or warrants to subscribe for
                         or

                                       5
<PAGE>

                         purchase any shares of capital stock of any class or of
                         any rights; or

                   (iv)  the approval of any stockholders of the Company shall
                         be required in connection with any reclassification of
                         the Common Stock of the Company, any consolidation or
                         merger to which the Company is a party, any sale or
                         transfer of all or substantially all of the assets of
                         the Company, or any compulsory share exchange whereby
                         the Common Stock is converted into other securities,
                         cash or property; or

                   (v)   the Company shall authorize the voluntary dissolution,
                         liquidation or winding up of the affairs of the
                         Company,

then the Company shall cause to be mailed to each Holder at their last addresses
as they shall appear upon the Warrant Register, at least 30 calendar days prior
to the applicable record or effective date hereinafter specified, a notice
stating (x) the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to
be taken, the date as of which the holders of Common Stock of record to be
entitled to such dividend, distributions, redemption, rights or warrants are to
be determined or (y) the date on which such reclassification, consolidation,
merger, sale, transfer or share exchange is expected to become effective or
close, and the date as of which it is expected that holders of Common Stock of
record shall be entitled to exchange their shares of Common Stock for
securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer, share exchange, dissolution, liquidation
or winding up; provided, however, that the failure to mail such notice or any
defect therein or in the mailing thereof shall not affect the validity of the
corporate action required to be specified in such notice.

            8. Payment of Exercise Price. The Holder shall pay the Exercise
Price in immediately available funds by certified check or bank draft payable to
the order of the Company or by wire transfer to an account designated by the
Company.

            9. Fractional Shares. The Company shall not be required to issue or
cause to be issued fractional Warrant Shares on the exercise of this Warrant.
The number of full Warrant Shares which shall be issuable upon the exercise of
this Warrant shall be computed on the basis of the aggregate number of Warrant
Shares purchasable on exercise of this Warrant so presented. If any fraction of
a Warrant Share would, except for the provisions of this Section 9, be issuable
on the exercise of this Warrant, the Company shall pay an amount in cash equal
to the Exercise Price multiplied by such fraction.

            10. Notices. Any and all notices or other communications or
deliveries hereunder shall be in writing and shall be deemed given and effective
on the earliest of (i) the date of transmission, if such notice or communication
is delivered via facsimile at the facsimile telephone number specified in this
Section prior to 5:00 p.m. (California time) on a business day, (ii) the
business day after the date of transmission, if such notice or communication is
delivered

                                       6
<PAGE>

via facsimile at the facsimile telephone number specified in this Section later
than 5:00 p.m. (California time) on any date and earlier than 11:59 p.m.
(California time) on such date, (iii) the business day following the date of
mailing, if sent by nationally recognized overnight courier service, or (iv)
upon actual receipt by the party to whom such notice is required to be given.
The addresses for such communications shall be: (i) if to the Company, to 157
Technology Drive, Irvine, CA 92618, Attention: CEO, or to facsimile no. (949)
788-6706, or (ii) if to the Holder, to the Holder at the address or facsimile
number appearing on the Warrant Register or such other address or facsimile
number as the Holder may provide to the Company in accordance with this Section
10.

            11. Warrant Agent. The Company shall serve as warrant agent under
this Warrant. The Company may appoint a new warrant agent upon notice to the
Holder in accordance with Section 10. Any corporation into which the Company may
be merged or any corporation resulting from any consolidation to which the
Company shall be a party or any corporation to which the Company transfers
substantially all of its corporate assets shall be a successor warrant agent
under this Warrant without any further act. Any such successor warrant agent
shall promptly cause notice of its succession as warrant agent to be mailed (by
first class mail, postage prepaid) to the Holder at the Holder's last address as
shown on the Warrant Register.

            12. Representations and Warranties of Holder. By accepting this
Warrant, Holder represents and warrants to the Company that the statements
contained in this Section 12 are correct and complete as of the date first
written above.

               (a) Business or Financial Expertise. Holder has either (i) a
pre-existing personal or business relationship with the Company or any of its
officers, directors or controlling persons that is of a nature and duration
which enables Holder to be aware of the character, business acumen and general
business and financial circumstances of the Company or (ii) by reason of
Holder's business or financial expertise or the business or financial experience
of his professional advisors who are unaffiliated with and who are not
compensated by the Company or any affiliate or selling agent of the Company,
directly or indirectly, the capacity to protect his own interests in connection
with his acquisition of the Warrant and the underlying Warrant Shares. Holder is
an "accredited investor" as defined in Rule 501 of Regulation D of the
Securities Act of 1933, as amended (the "Securities Act").

               (b) Awareness; No Distribution. Holder has had the opportunity to
ask questions about the Company's business affairs and financial condition, and
has acquired sufficient information about the Company to reach an informed and
knowledgeable decision to acquire the Warrant and underlying Warrant Shares.
Holder is acquiring the Warrant and underlying Warrant Shares for his own
account for investment purposes only and not with a view to, or for the resale
in connection with, any "distribution" thereof for purposes of the Securities
Act. Holder recognizes that the Warrant and underlying Warrant Shares are a
speculative investment involving a high degree of risk of loss and that Holder
could lose the entire amount of its investment. Holder is able to bear the
economic risk of this investment and at the present time could afford a complete
loss of this investment.

                                       7
<PAGE>

               (c) No Registration. Holder understands that the Warrant and
underlying Warrant Shares will be issued without registration under the
Securities Act and without qualification and/or registration under applicable
state securities laws ("Blue Sky Laws") in reliance upon specific exemptions
therefrom, which exemptions depend upon, among other things, the bona fide
nature of its investment intent as expressed herein. In this connection, Holder
understands that, in the view of the SEC, the statutory basis for such exemption
may be unavailable if its representations were predicated solely upon a present
intention to hold the Warrant and underlying Warrant Shares for the minimum
capital gains period specified under tax statutes, for a deferred sale, for or
until an increase or decrease in the market price of the Warrant Shares, or for
a period of one year or any other fixed period in the future.

               (d) Legend. Holder further understands that the Warrant Shares
must be held indefinitely unless subsequently registered and/or qualified under
the Securities Act and under the Blue Sky Laws or unless an exemption from
registration and/or qualification is otherwise available. Moreover, Holder
understands that the Company is under no obligation to register and/or qualify
the Warrant Shares. In addition, Holder understands that the certificate
evidencing the Warrant Shares will be imprinted with a legend in substantially
the form as follows which prohibits the transfer of the Warrant Shares unless
they are registered and/or qualified or such registration and/or qualification
is not required in the opinion of counsel for Holder.

               THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
               REGISTERED UNDER THE SECURITIES ACT OF 1933 AS AMENDED, AND MAY
               NOT BE OFFERED, SOLD, ASSIGNED OR TRANSFERRED, IN THE ABSENCE OF
               AN EFFECTIVE REGISTRATION STATEMENT UNDER SAID ACT OR UNLESS THE
               COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY
               SATISFACTORY TO THE COMPANY THAT REGISTRATION UNDER SAID ACT IS
               NOT REQUIRED.

               (e) Rule 144. Holder is aware of the provisions of Rule 144,
promulgated under the Securities Act, which, in substance, permits limited
public resale of "restricted securities" acquired, directly or indirectly, from
the issuer thereof (or from an affiliate of such issuer), in a non-public
offering subject to the satisfaction of certain conditions. Holder understands
that the Warrant Shares constitute "restricted securities" for the purposes of
Rule 144.

               (f) No Public Market. Holder further understands that at the time
it wishes to sell the Warrant Shares there may be no public market upon which to
make such a sale.

               (g) Risk. Holder further understands that in the event all of the
requirements of Rule 144 are not satisfied, registration under the Securities
Act, compliance with Regulation A, or some other registration exemption will be
required; and that, notwithstanding the fact that Rule 144 is not exclusive, the
Staff of the SEC has expressed its opinion that persons proposing to sell
private placement securities other than in a registered offering and otherwise
than pursuant to Rule 144 will have a substantial burden of proof in
establishing that an

                                       8
<PAGE>

exemption from registration is available for such offers or sales, and that such
persons and their respective brokers who participate in such transactions do so
at their own risk.

            13. Miscellaneous.

               (a) This Warrant shall be binding on and inure to the benefit of
the parties hereto and their respective successors and permitted assigns. This
Warrant may be amended only in writing signed by the Company and the Holder and
their successors and assigns.

               (b) Subject to Section 13(a), above, nothing in this Warrant
shall be construed to give to any person or corporation other than the Company
and the Holder any legal or equitable right, remedy or cause under this Warrant.
This Warrant shall inure to the sole and exclusive benefit of the Company and
the Holder.

               (c) This Warrant shall be governed by and construed and enforced
in accordance with the internal laws of the State of California without regard
to the principles of conflicts of law thereof. The Company and the Holder hereby
irrevocably submit to the exclusive jurisdiction of the state and federal courts
sitting in Orange County, California, for the adjudication of any dispute
hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in
any suit, action or proceeding, any claim that it is not personally subject to
the jurisdiction of any such court, or that such suit, action or proceeding is
improper. Each of the Company and the Holder hereby irrevocably waives personal
service of process and consents to process being served in any such suit, action
or proceeding by receiving a copy thereof sent to it at the address in effect
for notices to it under this instrument and in the manner set forth in Section
10 above, and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any manner permitted by law.

               (d) The headings herein are for convenience only, do not
constitute a part of this Warrant and shall not be deemed to limit or affect any
of the provisions hereof.

               (e) In case any one or more of the provisions of this Warrant
shall be invalid or unenforceable in any respect, the validity and
enforceability of the remaining terms and provisions of this Warrant shall not
in any way be affected or impaired thereby and the parties will attempt in good
faith to agree upon a valid and enforceable provision which shall be a
commercially reasonable substitute therefor, and upon so agreeing, shall
incorporate such substitute provision in this Warrant.

                                       9
<PAGE>

            IN WITNESS WHEREOF, the Company has caused this Warrant to be duly
executed by its authorized officer as of the date first indicated above.

                                    SPECTRUM PHARMACEUTICALS, INC.

                                    By:  /s/ Rajesh C. Shrotriya
                                    -------------------------------------------
                                    Name:  Rajesh C. Shrotriya, M.D.
                                    Title: Chief Executive Officer and President

                                       10
<PAGE>

FORM OF ELECTION TO PURCHASE

(To be executed by the Holder to exercise the right to purchase shares of Common
Stock under the foregoing Warrant)

To Spectrum Pharmaceuticals, Inc.:

            In accordance with the Warrant enclosed with this Form of Election
to Purchase, the undersigned hereby irrevocably elects to purchase __________
shares of Common Stock ("Common Stock"), $.001 par value per share, of Spectrum
Pharmaceuticals, Inc. (the "Company") encloses herewith $__________ in cash,
certified or official bank check or checks, which sum represents the aggregate
Exercise Price (as defined in the Warrant) for the number of shares of Common
Stock to which this Form of Election to Purchase relates, together with any
applicable taxes payable by the undersigned pursuant to the Warrant.

            The undersigned requests that certificates for the shares of Common
Stock issuable upon this exercise be issued in the name of:

PLEASE INSERT SOCIAL SECURITY OR
TAX IDENTIFICATION NUMBER:              ----------------------------------------

--------------------------------------------------------------------------------
                         (Please print name and address)

            If the number of shares of Common Stock issuable upon this exercise
shall not be all of the shares of Common Stock which the undersigned is entitled
to purchase in accordance with the enclosed Warrant, the undersigned requests
that a New Warrant (as defined in the Warrant) evidencing the right to purchase
the shares of Common Stock not issuable pursuant to the exercise evidenced
hereby be issued in the name of and delivered to:

--------------------------------------------------------------------------------
                         (Please print name and address)

            By signing below, the Holder represents and warrants to the Company
that the statements contained in Section 12 are true and correct as of the date
hereof, as if given on the date hereof.

Dated:  __________, ____           Name of Holder:

                                   (Print)
                                   ---------------------------------------------
                                   (By:)
                                   ---------------------------------------------
                                   (Name:)
                                   ---------------------------------------------
                                   (Title:)
                                   ---------------------------------------------
                                   (Signature must conform in all
                                   respects to name of holder as
                                   specified on the face of the Warrant)

                                       11
<PAGE>

                               FORM OF ASSIGNMENT

           [To be completed and signed only upon transfer of Warrant]

            FOR VALUE RECEIVED, the undersigned hereby sells, assigns and
transfers unto ____________________ the right represented by the Warrant
enclosed with this Form of Assignment to purchase __________ shares of Common
Stock of Spectrum Pharmaceuticals, Inc. to which the Warrant relates and
appoints ____________________ attorney to transfer said right on the books of
Spectrum Pharmaceuticals, Inc. with full power of substitution in the premises.

Dated:  __________, ____          ----------------------------------------------
                                  (Signature must conform in all
                                  respects to name of holder as
                                  specified on the face of the Warrant)

                                  ----------------------------------------------
                                  Address of Transferee

                                  ----------------------------------------------

                                  ----------------------------------------------
In the presence of:

-------------------------------------

                                       12<PAGE>
                                                                    EXHIBIT 10.1

                            FIRST AMENDMENT TO LEASE

I.       PARTIES AND DATE.

         This First Amendment to Lease (the "Amendment") dated March 25, 2004,
is by and between the IRVINE COMPANY, a Delaware corporation ("Landlord"), and
SPECTRUM PHARMACEUTICALS, INC., a Delaware corporation ("Tenant"), formerly
known as Neotherapeutics, Inc.

II.      RECITALS.

         On January 16, 1997, Landlord and Tenant entered into a lease ("Lease")
for space in a building located at 157 Technology Drive, Irvine, California
("Premises").

         Landlord and Tenant each desire to modify the Lease to extend the Lease
Term, to adjust the Basic Rent, and to make such other modifications as are set
froth in "III. MODIFICATIONS" next below.

III.     MODIFICATIONS.

         A. Basic lease Provisions. The Basic Lease Provisions are hereby
amended as follows:

                  1.       Item 5 is hereby deleted in its entirety and
                  substituted therefore shall be the following:

                           "5. Lease Term: The Term of this Lease shall expire
                           at midnight on June 30, 2009"

                  2.       Item 6 is hereby amended by adding the following:

                           "Commencing July 1, 2004, the Basic Rent shall be
                           Sixteen Thousand Three Hundred Twenty Dollars
                           ($16,320.00) per month.

                           Commencing May 1, 2005, the Basic Rent shall be
                           Thirty Two Thousand Six Hundred Four Dollars
                           ($32,604.00) per month, based on $.95 per rental
                           square foot.

                           Commencing July 1, 2005, the Basic Rent shall be
                           Thirty Four Thousand Three Hundred Twenty Dollars
                           ($34,320.00) per month, based on $1.00 per rentable
                           square foot.

                           Commencing July 1, 2006, the Basic Rent shall be
                           Thirty Six Thousand Thirty-Six Dollars ($36,036.00)
                           per month, based on $1.05 per rentable square foot.

                           Commencing July 1, 2007, the Basic Rent shall be
                           Thirty Seven Thousand Seven Hundred Fifty-Two Dollars
                           ($37,752.00) per month, based on $1.10 per rentable
                           square foot.

                           Commencing July 1, 2008, the Basic Rent shall be
                           Thirty Nine Thousand Four Hundred Sixty-Eight Dollars
                           ($39,468.00) per month, based on $1.15 per rentable
                           square foot.

                  3.       Item 12 is hereby deleted in its entirety and
                  substituted therefore shall be the following:

                                       1

<PAGE>

                           "12. Address for Payments and Notices:

                                LANDLORD

                                THE IRVINE COMPANY
                                dba Office Properties
                                8105 Irvine Center Drive, Suite 300
                                Irvine, CA 92618
                                Attn: Vice President, Operations, Technology
                                      Portfolio

                                with a copy of notices to:

                                THE IRVINE COMPANY
                                dba Office Properties
                                8105 Irvine Center Drive, Suite 300
                                Irvine, CA 92618
                                Attn: Senior Vice President, Operations
                                Office Properties

                                TENANT

                                SPECTRUM PHARMACEUTICALS, INC.
                                157 Technology
                                Irvine, CA 92618"

         B. Right to Extend the Lease. The reference in Section 3.1(b) to "two
(2) successive options to extend the Term" is hereby revised to " one (1) option
to extend the Term of this Lease for a single period of sixty (60) months."

         C. Operating Expenses. Effective as of July 1, 2004, the last two (2)
sentences of the initial paragraph of Section 4.2(c), dealing with
"Controllable" Building Costs, are hereby deleted in their entirety and shall
have no further force or effect.

         D. Utilities and Services. The following provisions are hereby added to
the end of Section 6.1 of the Lease entitled "Utilities and Services";

                  "Tenant shall also pay to Landlord as an item of additional
                  rent, so as long as the appropriate Energy Monitoring Systems
                  are in place, within ten (10) days after receipt of Landlord's
                  statement or invoice therefor, a reasonable charge, estimated
                  between $5.00 and $10.00 per hour pending the size of the HVAC
                  units (which shall be in addition to the electricity charge
                  paid to the utility provider) for Tenant's "after hours" usage
                  of each HVAC unit servicing the second floor of the Premises
                  excluding any charges related to the use and operation of the
                  server room's 24-Hour HVAC unit. If the HVAC unit(s) serve
                  only the Premises, "after hours" shall mean more than three
                  hundred (300) hours of usage during any month during the Term.
                  "After hours" usage shall be determined based upon the
                  operation of the applicable HVAC unit during each of the
                  foregoing periods on a "non-cumulative" basis (that is,
                  without regard to Tenant's usage or nonusage of other unit(s)
                  serving the Premises, or of the applicable unit during other
                  periods of the Term). Tenant acknowledges that the costs
                  incurred and evidenced by landlord related to providing
                  utilities above and beyond what is currently being provided to
                  the Building, including, without limitation, telephone lines,
                  may be charged to Tenant."

                                       2
<PAGE>

         E. Rights of Parties. The reference in the second (2nd) paragraph of
Section 9.1(b) to "thirty (30) days" is hereby revised to "fifteen (15) business
days".

         F. Acceptance of Premises. Tenant acknowledges that the lease of the
Premises pursuant to this Amendment shall be on an "as-is" basis without further
obligation on landlord's part as to improvements whatsoever, except that
Landlord shall shampoo all carpet, wax all VCT and linoleum, wash interior
perimeter windows, and shall detail clean the interior of the building, to
include vacuuming, dusting, cleaning of restrooms, wiping air vents and washing
glass partitions, and except as otherwise required by the terms of the Lease.

IV.     GENERAL.

         A. Effect of Amendments. The Lease shall remain in full force and
effect except to the extent that it is modified by this Amendment.

         B. Entire Agreement. This Amendment embodies the entire understanding
between Landlord and Tenant with respect to the modifications set forth in "III.
MODIFICATIONS" above and can be changed only by a writing signed by Landlord and
Tenant.

         C. Counterparts. If this Amendment is executed in counterparts, each is
hereby declared to be an original; all, however, shall constitute but one and
the same amendment. In any action or proceeding, any photographic, photostatic,
or other copy of this Amendment may be introduced into evidence without
foundation.

         D. Defined Terms. All words commencing with initial capital letters in
this Amendment and defined in the Lease shall have the same meaning in this
Amendment as in the Lease, unless they are otherwise defined in this Amendment.

         E. Corporate and Partnership Authority. If Tenant is a corporation or
partnership, or is comprised of either or both of them, each individual
executing this Amendment for the corporation or partnership represents that he
or she is duly authorized to execute and deliver this Amendment on behalf of the
corporation or partnership and that this Amendment is binding upon the
corporation or partnership in accordance with its terms.

         F. Attorneys' Fees. The provisions of the Lease respecting payment of
attorneys' fees shall also apply to this Amendment. However, Tenant shall not be
responsible for any Landlord related attorneys' fees in connection with the
negotiation and execution of this First Amendment to Lease.

V.      EXECUTION.

        Landlord and Tenant executed this Amendment on the date as set forth in
"I. PARTIES AND DATE," above.

LANDLORD:                                   TENANT:

THE IRVINE COMPANY,                         SPECTRUM PHARMACEUTICALS, INC.
a Delaware Corporation                      a Delaware corporation

By  /s/ DONALD S. MCNUTT                    By  /s/ RAJESH C. SHROTRIYA
    ------------------------------              --------------------------------
    Donald S. McNutt, Senior Vice               Name: Rajesh C. Shrotriya
    President Leasing, Office                   Title: CEO
    Properties

By  /s/ STEVEN E. CLATON                    By  /s/ SHYAM KUMARIA
    ------------------------------              --------------------------------
    Steven E. Claton, Vice President            Name: Shyam Kumaria
    Operations, Office Properties               Title: VP - Finance

                                       3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00066-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00066-of-00352.parquet"}]]